Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great trade!
it's remarkable how you always sell around the top.
Your really have great trading/hunting skills.
MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists
Allowance Broadens Portfolio for the Treatment of Obesity and Related Diseases
BOTHELL, WA--(Marketwire - 04/12/10) - MDRNA, Inc. (NASDAQ:MRNA - News), a leading RNA interference (RNAi)-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 12/234,547 covering formulations for the intranasal delivery of Y2 receptor selective agonists.
Y2-receptor agonists are a family of peptides (pancreatic polypeptide, peptide YY, and neuropeptide Y) that play a central role in caloric intake. The natural release of these peptides in association with meals directly influences how efficient and effective the body utilizes sugars, carbohydrates and other nutrients. Y2-receptor agonists can regulate food intake at the level of the brain, pancreas, and intestinal tract, and may provide treatment to prevent overeating and excessive weight gain, and the numerous adverse health effects associated with obesity.
"MDRNA's focus remains the development of therapeutic products based on RNAi, however we believe that our legacy nasal assets have significant value," said J. Michael French, President and CEO of MDRNA. "This patent allowance considerably broadens the scope of protection for our intranasal formulations used in the treatment of high profile diseases such as obesity and related diseases. Based on the breadth of the allowed claims and the success of our formulations to deliver a drug via a nasal spray, we believe our nasal delivery technology has excellent commercial potential."
While representing an attractive means of therapy, peptide-based drugs generally require injections, and in the case of obesity and related diseases, chronic administration. Intranasal sprays provide an easy and convenient means of therapy, and are appropriate for chronic use. To this end, intranasal formulations developed by MDRNA have demonstrated effective and safe delivery in clinical trials of numerous peptides, including Y2-receptor agonists. Furthermore, commercial scale procedures and processes for these formulations have been established and can be expected to allow for rapid development and commercialization.
A patent allowance confirms the substantive examination of a patent application and will result in a final issuance of a U.S. patent once an administrative process is completed.
About MDRNA's Technology
MDRNA has a broad intellectual property estate that encompasses four key RNAi technology platforms: siRNA constructs, chemistry, nucleic acid delivery, and gene targets. The MDRNA-owned siRNA constructs and chemistry include its proprietary UsiRNA construct, which is a duplex siRNA chemically modified with non-nucleotide acyclic monomers (UNAs), and is distinct from the standard siRNA construct used by others in the industry. UsiRNAs are fully recognized by the RNAi machinery and provide for potent RNAi activity while specific placement of UNAs in a duplex siRNA minimizes potential off-target effects by the guide strand and reduces undesired passenger strand activity. Furthermore, UsiRNAs escape the surveillance mechanisms associated with cytokine induction, and provide protection from nuclease degradation.
The MDRNA delivery platforms include DiLA2 and nanoparticle forming peptides. DiLA2 is an MDRNA proprietary delivery platform of novel synthetic di-alklylated amino acid compounds used to make liposomal delivery formulations. The DiLA2 platform enables MDRNA to tailor the charge, linker and acyl chains of amino acids in order to configure liposomes for delivery to target tissues of interest. In addition, the platform is designed to permit attachment of various peptides and other targeting molecules to improve a variety of delivery characteristics. The MDRNA peptide nanoparticle platform includes exclusively in-licensed and developed IP surrounding the use of peptides for nanoparticle formulations that increase cellular uptake and endosomal release of siRNAs. MDRNA is currently biopanning its patented phage display library to identify additional peptides for targeted delivery, cellular uptake and endosomal release of siRNA.
MDRNA owns or controls 16 issued or allowed patents, and has 36 pending patent applications, 126 pending foreign patent applications and 7 PCT applications.
This statement was made in 2005
long before we even heard of the Obama Stimulis/HealthCare Reform.
It only could get better, the future of MMRF looks bright...
This statement was made in 2005
long before we even heard of the Obama Stimulis/HealthCare Reform.
It only could get better, the future of MMRF looks bright...
Pfizer Joins Novartis-Roche-AstraZeneca
All have working relationships with MDRNA.
French knows what he is doing,he keeps the rich suitors interested.
I will keep an eye on MESAQ.
it looks good but i want to do some more DD.
thanks in advance
for all your time and efforts you've put into MMRF
for keeping us informed.
What do you think about IVFH?
This is also a REAL company with a $7.59 million revenue
and a small Operating Profit of Over $195,000.
Does anyone heard something from Tom G. lately?
Cequent will have certain cash amounts on hand at the close of the acquisition which will fund the combined operations into December 2010. Great news
i bought some more shares today @.129
but the MM's showed it as a sell.
0.129 10000 OBB 10:27:41
the RNAi drugs shop said it still expects to fulfill its goal of forging two major research and development alliances with big pharma or biotech partners, potentially ones with which MDRNA already has ongoing early-stage collaborations, the officials said.
MDRNA Names Indication for First IND, Says Early-Stage Collaborations Will Yield Bigger Deals
March 25, 2010
MDRNA officials this week said that it remains on track to filing an investigational new drug application for its bladder cancer therapy by the end of the year, and disclosed that it has chosen the non-muscle-invasive form of the disease as the first indication pursued under the program.
Additionally, the RNAi drugs shop said it still expects to fulfill its goal of forging two major research and development alliances with big pharma or biotech partners, potentially ones with which MDRNA already has ongoing early-stage collaborations, the officials said.
Separately this week, MDRNA also announced that it has acquired from Valeant Pharmaceuticals North America an intellectual property estate covering bridged nucleic acids, a move that it expects will enhance its ability to develop RNAi and, potentially, non-RNAi therapeutics.
During a conference call held to discuss the company's newly released fourth-quarter financial results, CSO Barry Polisky said that the bladder cancer indication was selected based on discussions with key clinicians regarding which patients with the disease were most "under-served" by existing treatments.
He added that MDRNA is currently conducting non-human primate safety and tolerability studies with its bladder cancer candidate, and thus far, "direct installation of our lead formulation into [the] non-human bladder, followed by a two-hour retention time, was observed to be well-tolerated with no signs of toxicity."
Additionally, "urinalysis and serum chemistry and hematology values were normal," he said. "Tissue histology is underway and will be completed very soon."
Meanwhile, efforts to ramp up manufacturing of the drug to meet both clinical and commercial requirements are underway in collaboration with an undisclosed "leading contract manufacturing organization," Polisky noted.
In regards to the BNA technology, he said that the acquisition "further increases the versatility of [MDRNA's proprietary] UsiRNA and meroduplex [siRNA] constructs."
According to MDRNA, BNAs are "novel nucleoside analogs in which the flexible ribose sugar is locked into a rigid conformation by a small chemical linker. When included in single- or double-stranded oligonucleotides, the highly stable A-form of RNA or DNA is favored, resulting in increased thermal stability of a duplex or higher affinity of a single strand for its complementary target," such as mRNA.
"In addition, BNAs provide resistance to nuclease degradation," MDRNA added.
The technology "provides us with the ability to pursue single-stranded constructs with non-RNAi mechanisms of action," Polisky noted. However, he stressed that its near-term importance for MDRNA lies in its ability to help the company develop "novel siRNA constructs" by enhancing the "structural versatility and [tuning] the details of the double-stranded molecules in the RNAi pathways.
"For the foreseeable future, our focus is on siRNA and the applications that BNA will provide in the work we've already done," he explained. "The extent to which we will go beyond RNAi mechanism is under discussion … and in the early stages. We don't have a specific program in mind here."
MDRNA President and CEO Michael French added during the call that "we are still siRNA-focused. We think this [technology] brings some additional capability to looking at [RNAi] constructs and making sure that we can apply constructs effectively as therapeutic modalities."
Separately this week, MDRNA also announced that it has acquired the intellectual property estate covering bridged nucleic acids from Valeant Pharmaceuticals North America, a move that it expects will enhance its ability to develop RNAi and, potentially, non-RNAi therapeutics.
http://www.genomeweb.com/rnai/mdrna-names-indication-first-ind-says-early-stage-collaborations-will-yield-bigg
DANR is looking good but
What do you think about IVFH?
MRNA to File Bladder Cancer
IND by Year End, Eyes Two Big Pharma Deals in '10
http://www.genomeweb.com/rnai/mdrna-file-bladder-cancer-ind-year-end-eyes-two-big-pharma-deals-10
MRNA to File Bladder Cancer
IND by Year End, Eyes Two Big Pharma Deals in '10
http://www.genomeweb.com/rnai/mdrna-file-bladder-cancer-ind-year-end-eyes-two-big-pharma-deals-10
MDRNA, Eyes Two Big Pharma Deals in '10
February 11, 2010
MDRNA's top executive this week confirmed that the company has moved its bladder cancer program to the head of its pipeline, and that it would yield an investigational new drug application filing — the firm's first — in the fourth quarter.
At the same time, MDRNA President and CEO Michael French, speaking at this year's BIO-CEO and Investor conference held in New York, said that the company was on track to forge two full-fledged research and development collaborations with a big pharma partner in 2010. Previously, the company had said that it expected to sign only a single deal this year (see RNAi News, 11/19/2009).
After reorganizing last year from intranasal delivery firm Nastech Pharmaceutical into a pure-play RNAi drug shop with a variety of drug-development programs, MDRNA narrowed its focus onto a single indication: liver cancer (see RNAi News, 3/26/2009).
Less than six months later, however, the company announced that it had added bladder cancer to its pipeline, citing positive results in rodent studies and delivery advantages given the ease with which a drug can be locally administered to the bladder (see RNAi News, 8/6/2009).
Since then, the bladder cancer effort has steadily gained steam, and by October, MDRNA was weighing the possibility that the program could enter clinical testing before a liver cancer candidate (see RNAi News, 10/15/2009). Now, it appears that it will, while a second IND, "likely in liver cancer," is slated to be filed with US regulators in the first half of 2011, French said at BIO-CEO.
He added at the conference that MDRNA will select a lead bladder cancer candidate for the IND "in the coming weeks," and that the drug will have two targets. Already, the company has released rodent data demonstrating knockdown of two oncology targets, survivin and polo-like kinase 1, using its proprietary UsiRNA molecules formulated in its DiLA2 liposomal delivery vehicles.
As such, those two are the "top targets" being considered, although the company is evaluating others, French told RNAi News.
At the same time, MDRNA continues to pursue big pharma partnerships, and is poised to meet its previously stated goal of inking one before the end of the second quarter. The company is now also expecting to sign a second before the end of the year.
"These collaborations, we would expect, [will be] somewhere in the $10-to-$20 million up-front range, [and include] R&D funding, downstream milestones, and royalties," French said during the conference.
While alliances with bigger players have a number of benefits for smaller biotech players, such as providing access to scientific expertise, the financial upside is a key consideration, especially for MDRNA, which French said currently has enough cash to last into the second quarter.
Previously, the company had said that it expected to sign only a single partnership agreement this year.
MDRNA to File Bladder Cancer IND by Year End, Eyes Two Big Pharma Deals in '10
http://www.genomeweb.com/rnai/mdrna-file-bladder-cancer-ind-year-end-eyes-two-big-pharma-deals-10
What did the second glance say.
i would really appreciate you imput (through PM)
thanks in advance
if you have any questions, shoot !
please let met know what your conclusion is.
like you can see their isn't much selling...
OS only 100m
This could become a second BGOI...
What do you think of HMGP?
if volume or mono would come in, it could go real fast
because most of the shareholders are in @ much higher prices.
They still own some assets ...
008X009
looking good
Do you have any idea of the current OS?
I tried to buy some during the morning dip
but the MM didn't filled my order.
it could be a good buy if (buying)volume comes in ...
without volume we go back down imo
Have you heard anything more about VTPI? PSC?
it looks like the seller is gone ... this time for good?
it's nice to see some compatriots.
What do you think of hemi and
how do you see the shareprice as well as the company evolving?
you can send me a pm in duth if you want.
The good news is that someone is loading up shares!
We don't know who's buying but maybe
we will hear something from KAA in time.
Do you have any idea what happend with that $475k?
since the horizontal drilling didn't happend...
0.006 950000 OTO 15:53:20
Was this trade a BUY or a SELL?
Great close @.007 with high volume
the same rumblings that predicted the sirna buyout?
Are you still in VTPI? heard anything more?
i might be buying because it looks like the selling dried up.
this could be the bottom...
Do you still check your pmbox @hotstockmarket?
because i want to ask you a question in private.
i looks like the seller is/was back!
from my POV a bounce will depend upon PSC ...
Great Summary of the CC
This is A MUST READ for mmrf investors!
i really appreciate your postings.
You are just giving us your opinions/facts,
what we think/make of it is our own opinion!
We shall see what the future brings ...
What or who is psc?
how reliable is your tip that we will see a big bounce...
Witch stock is the best buy right now in your opinion?
BGOI, VSYM, or others...
i would love to talk/say/know more in private
fa005397 @ yahoo .com
i would love to hear from you
thanks in advance